このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Infinity Pharmaceuticals マネジメント
マネジメント 基準チェック /14
現在、CEO に関する十分な情報がありません。
主要情報
Seth Tasker
最高経営責任者
n/a
報酬総額
| CEO給与比率 | n/a |
| CEO在任期間 | 7.7yrs |
| CEOの所有権 | n/a |
| 経営陣の平均在職期間 | データなし |
| 取締役会の平均在任期間 | 6yrs |
経営陣の近況
Recent updates
Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?
Nov 10
Infinity Pharmaceuticals: Waiting For A Deal
Sep 08Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?
May 23We're Hopeful That Infinity Pharmaceuticals (NASDAQ:INFI) Will Use Its Cash Wisely
Dec 29Investigating Infinity Pharmaceuticals
Nov 25Infinity Pharmaceuticals (NASDAQ:INFI) Is In A Good Position To Deliver On Growth Plans
Jul 18Increases to Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) CEO Compensation Might Cool off for now
Jun 03Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Deliver On Growth Plans?
Apr 13Are Institutions Heavily Invested In Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) Shares?
Feb 19Can You Imagine How Jubilant Infinity Pharmaceuticals' (NASDAQ:INFI) Shareholders Feel About Its 147% Share Price Gain?
Jan 15
Infinity Pharma to start new registration-enabling eganelisib study in urothelial cancer
Jan 06Will Infinity Pharmaceuticals (NASDAQ:INFI) Spend Its Cash Wisely?
Dec 11Infinity Pharma slides after eganelisib data presentation at Breast Cancer Symposium
Dec 09Infinity Pharmaceutical Reaching Vital New Staging Posts
Dec 01CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2023 | n/a | n/a | -US$41m |
| Mar 31 2023 | n/a | n/a | -US$43m |
| Dec 31 2022 | n/a | n/a | -US$44m |
| Sep 30 2022 | n/a | n/a | -US$47m |
| Jun 30 2022 | n/a | n/a | -US$47m |
| Mar 31 2022 | n/a | n/a | -US$46m |
| Dec 31 2021 | n/a | n/a | -US$45m |
| Sep 30 2021 | n/a | n/a | -US$44m |
| Jun 30 2021 | n/a | n/a | -US$43m |
| Mar 31 2021 | n/a | n/a | -US$41m |
| Dec 31 2020 | US$1m | US$386k | -US$40m |
| Sep 30 2020 | n/a | n/a | -US$41m |
| Jun 30 2020 | n/a | n/a | -US$43m |
| Mar 31 2020 | n/a | n/a | -US$44m |
| Dec 31 2019 | US$653k | US$368k | -US$47m |
| Sep 30 2019 | n/a | n/a | -US$44m |
| Jun 30 2019 | n/a | n/a | -US$19m |
| Mar 31 2019 | n/a | n/a | -US$16m |
| Dec 31 2018 | n/a | n/a | -US$11m |
| Sep 30 2018 | n/a | n/a | -US$10m |
| Jun 30 2018 | n/a | n/a | -US$31m |
| Mar 31 2018 | n/a | n/a | -US$41m |
| Dec 31 2017 | US$1m | US$320k | -US$42m |
報酬と市場: Sethの 総報酬 がUS市場の同規模の企業と比較して妥当かどうかを判断するにはデータが不十分です。
報酬と収益: Sethの報酬は増加しましたが、会社は利益を上げていません。
CEO（最高経営責任者
Seth Tasker (44 yo)
7.7yrs
在職期間
US$1,435,444
報酬
Mr. Seth A. Tasker, J.D., has been Senior Vice President, General Counsel and Secretary at Infinity Pharmaceuticals, Inc. since December 2019 and has been its CEO since September 1, 2023 and had been its C...
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Independent Director | 17.5yrs | US$93.08k | 0.24% $ 0.2 | |
| Lead Independent Director | 12yrs | US$125.82k | 0.017% $ 0.01 | |
| Independent Director | 5.9yrs | US$85.58k | 0.0097% $ 0.009 | |
| Member of Scientific Advisory Board | 6yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 6yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 6yrs | データなし | データなし | |
| Independent Director | 4yrs | US$83.08k | 0% $ 0 | |
| Member of Scientific Advisory Board | 6yrs | データなし | データなし | |
| Chairman of Scientific Advisory Board | 4yrs | US$759.67k | データなし | |
| Chair of Clinical Advisory Board | no data | US$73.08k | 0.012% $ 0.01 | |
| Member of Clinical Advisory Board | no data | データなし | データなし | |
| Member of Clinical Advisory Board | no data | データなし | データなし |
6.0yrs
平均在職期間
71yo
平均年齢
経験豊富なボード: INFI.Qの 取締役会 は 経験豊富 であると考えられます ( 6年の平均在任期間)。